Adults with mild to severe obstructive sleep apnea achieved lower disease severity with AD109, an oral combination drug, at ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Testosterone is being hailed as the secret to better energy, mood, and sex drive. Here’s what experts say about when it ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is initiating a Phase 2 ...

Experts say there are some components of the cannabis plant “that appear to be helpful for some people with regard to sleep." ...

Adding sotatercept to standard therapy within a year of diagnosis lowers the risk for clinical worsening in patients with ...

Natera has announced positive results from the Phase III IMvigor011 clinical trial for muscle-invasive bladder cancer (MIBC).

A clinical pharmacist has pinpointed a popular medication in the UK she claims has remedial effects which 'aren't much better ...

The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...

A clinical pharmacist in the UK believes there's one common item on pharmacy shelves that simply isn't worth the money, ...

This is the second time within months that Roche’s potential first-in-class TIGIT product has failed a Phase III study.

Topline data were announced from two phase 3 trials evaluating ulixacaltamide in patients with essential tremor.